Drug Type Oncolytic virus |
Synonyms Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection, 重组人IL-12/15单纯疱疹I型双调控溶瘤病毒(复诺健生物科技有限公司), VG203 + [1] |
Target |
Action stimulants, agonists |
Mechanism IL-12R stimulants(Interleukin-12 receptor stimulants), IL15R agonists(Interleukin-15 receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 09 Dec 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 09 Dec 2025 | |
| Solid tumor | Phase 1 | - | - | |
| Breast Cancer | Preclinical | Canada | 27 Jul 2022 | |
| Ovarian Cancer | Preclinical | Canada | 27 Jul 2022 | |
| Renal Cell Carcinoma | Preclinical | Canada | 27 Jul 2022 |





